GILD - Gilead Sciences - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3755581036

HIV/Aids, Cancer, Hepatitis, COVID-19, Fungal Infections, Pulmonary Hypertension

Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines to address unmet medical needs globally.

The company has a diverse portfolio of products for treating life-threatening diseases, including HIV/AIDS, COVID-19, viral hepatitis, and cancer. For instance, its HIV/AIDS treatment options include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs, and Atripla. Veklury is its intravenous injection for treating COVID-19, while Epclusa, Harvoni, Vemlidy, and Viread are used to treat viral hepatitis.

In the field of oncology, Gilead offers Yescarta, Tecartus, and Trodelvy to combat various types of cancer. Additionally, Letairis is used to treat pulmonary arterial hypertension, and AmBisome is a liposomal formulation for treating serious invasive fungal infections.

Gilead has established collaborations with numerous companies, including Arcus Biosciences, Merck Sharp & Dohme Corp., Pionyr Immunotherapeutics Inc., and others, to accelerate the development of new treatments. One notable collaboration is with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.

Founded in 1987, Gilead Sciences is headquartered in Foster City, California, and is committed to advancing medical innovation to improve patient lives worldwide. To learn more about the company and its initiatives, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for GILD - Gilead Sciences  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for GILD - Gilead Sciences  - Stock Price & Dividends

GILD Stock Overview

Market Cap in USD 88,119m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1992-01-22

GILD Stock Ratings

Growth 5y 18.5
Fundamental 52.4
Dividend 56.43
Rel. Performance vs Sector -2.84
Analysts 3.71/5
Fair Price Momentum 76.43 USD
Fair Price DCF 167.17 USD

GILD Dividends

Dividend Yield 12m 4.35%
Yield on Cost 5y 5.48%
Dividends CAGR 5y 3.55%
Payout Consistency 100.0%

GILD Growth Ratios

Growth 12m -5.55%
Growth Correlation 12m -44%
Growth Correlation 3m 15%
CAGR 5y 4.75%
CAGR/Mean DD 5y 0.37
Sharpe Ratio 12m -0.46
Alpha vs SP500 12m -18.62
Beta vs SP500 5y weekly 0.37
ValueRay RSI 83.98
Volatility GJR Garch 1y 23.05%
Price / SMA 50 6.1%
Price / SMA 200 -2.98%
Current Volume 4538.8k
Average Volume 20d 8789.5k

External Links for GILD Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of GILD stocks?
As of July 14, 2024, the stock is trading at USD 69.96 with a total of 4,538,804 shares traded.
Over the past week, the price has changed by +4.90%, over one month by +10.07%, over three months by +4.04% and over the past year by -5.91%.
What are the forecast for GILD stock price target?
According to ValueRays Forecast Model, GILD Gilead Sciences will be worth about 82.9 in July 2025. The stock is currently trading at 69.96. This means that the stock has a potential upside of +18.51%.
Issuer Forecast Upside
Wallstreet Target Price 81.2 16.1
Analysts Target Price 85.5 22.2
ValueRay Target Price 82.9 18.5

Gilead Sciences Inc: A Deep Dive into its History, Business, and Market Status

History of Gilead Sciences Inc

Founded in 1987, Gilead Sciences Inc has established itself as a leading biopharmaceutical company. With a focus on discovering, developing, and commercializing innovative therapeutics in areas of unmet medical need, the company has made significant strides in the medical field, especially in antiviral drugs to treat patients infected with HIV, hepatitis B, hepatitis C, and influenza.

Core Business and Side Ventures

The core business of Gilead Sciences revolves around its robust antiviral drug portfolio, which has been pivotal in treating and managing HIV/AIDS and viral hepatitis. This segment not only brought commercial success but also established Gilead as a leader in the antiviral domain.

Beyond its antiviral lineup, Gilead has diversified its portfolio to include oncology, inflammatory and respiratory diseases, and cardiovascular conditions. This diversification reflects the company's commitment to addressing more therapeutic areas. Additionally, Gilead has embraced partnerships and acquisitions as strategies to bolster its R&D capabilities and expand its product offerings.

Current Market Status

As of now, Gilead Sciences continues to be a significant player in the pharmaceutical industry, maintaining a strong market position. The demand for its antiviral products remains high, contributing substantially to its revenue. Moreover, Gilead's efforts in expanding into new therapeutic areas and strategic acquisitions have positioned it well for future growth amid a competitive landscape.

Despite facing challenges such as patent expirations and market competition, Gilead's innovative pipeline and proactive business strategies give it a promising outlook. The company's commitment to improving patient care globally keeps it at the forefront of the biopharmaceutical industry.